Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.
Kazuo Oshimi
https://pubmed.ncbi.nlm.nih.gov/28717070/Actively Recruiting
Led by Necmettin Erbakan University · Updated on 2026-01-26
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating the relationship between large granular lymphocytes LGLs and treatment outcomes in participants with metastatic non-small cell lung cancer NSCLC receiving nivolumab as a second-line therapy. LGLs are a type of large lymphocyte, mostly natural killer cells or T lymphocytes, which cannot be measured by standard blood tests but can be detected by peripheral smear. This study aims to understand how baseline and three-month LGL levels relate to treatment response and clinical parameters in these patients. Participants with metastatic NSCLC will be observed while receiving nivolumab, an immune checkpoint inhibitor targeting PD-1, which has shown meaningful survival benefits compared to chemotherapy. The study focuses on measuring LGL levels at the start and after three months of treatment. Nivolumab is approved for second-line use in advanced NSCLC following platinum-based chemotherapy. This observational study does not involve assigning treatments but follows patients receiving standard care with nivolumab. During the study, participants will undergo evaluations including objective response rate assessments according to RECIST 1.1 criteria up to 12 weeks, with longer-term monitoring of progression-free survival and overall survival from July 2025 through July 2027. Researchers will collect clinical data and monitor safety outcomes while tracking LGL levels to assess their prognostic value. The study is expected to provide insights over approximately two years of follow-up.
CONDITIONS
Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
A
Ahmet Oruç MD
M
Mehmet Artaç MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Necmettin Erbakan University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From enrollment to 12 weeks
Participants with metastatic non-small cell lung cancer treated with nivolumab are monitored to assess large granular lymphocyte levels and clinical outcomes.
Baseline and 3-month visits for blood sample collection and clinical evaluation
Duration - Up to 2 years from July 2025 to July 2027
Participants are followed to evaluate progression-free and overall survival after initial treatment monitoring.
Periodic follow-up visits as scheduled for survival assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Kazuo Oshimi
https://pubmed.ncbi.nlm.nih.gov/28717070/M R Conroy, H O'Sullivan, D C Collins...
https://pubmed.ncbi.nlm.nih.gov/39516713/Hazem I Assi, Alice O Kamphorst, Nour M Moukalled...
https://pubmed.ncbi.nlm.nih.gov/29211297/Freddie Bray, Mathieu Laversanne, Hyuna Sung...
https://pubmed.ncbi.nlm.nih.gov/38572751/Hossein Borghaei, Scott Gettinger, Everett E Vokes...
https://pubmed.ncbi.nlm.nih.gov/33449799/Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson...
https://pubmed.ncbi.nlm.nih.gov/27718847/Tony S K Mok, Yi-Long Wu, Iveta Kudaba...
https://pubmed.ncbi.nlm.nih.gov/30955977/Necmettin Erbakan University
Lead Sponsor